Darwin Discovery Limited

Medeva Europe Limited

Other

Andrew John Richards

Hazel Judith Bardsley

Robert William Gristwood

Nicholas Robert Pope

Jeffrey Charles Edwards

Julian Clive Gilbert

A well testing system and well testing method is described which can be operated as a closed system with no production of hydrocarbons outside the well or gas can be separated and flared at surface giving minimal environmental impact with the liquid hydrocarbon being re-injected. This is achieved by providing a string with at least two well conduits which may be arranged in a concentric or non-concentric parallel configuration. One conduit is used to produce formation fluids to surface or to produce/store unrepresentative initial flow products and the other conduit is used to store formation fluid. The storage conduit can be filled from the top (surface) or the bottom of the well. In a preferred arrangement a valve is provided between the storage conduit and the well annulus for well pressure control, and a shut-in or test valve, which is controllable from surface, is disposed in the non-storage production conduit. A flow control valve is provided at the lower end of the string or at surface and the size of the valve opening is controllable to allow formation fluid to enter the storage string at a controlled rate, so that the formation fluid flowing time is increased to maximize the radius of investigation into the formation to a similar order of magnitude of existing production tests and extended well tests, which are typically two to three times the order of magnitude of the radius of investigation of a wireline formation test. Other aspects and embodiments of the invention are described.

Well testing system

A method of treating a subject that is undergoing methylphenidate therapy and concomitant therapy with another drug undergoes or interferes with P.sub.450 metabolism, wherein the methylphenidate is d-threo-methylphenidate.

Composition comprising methylphenidate and another drug

Aqueous pharmaceutical compositions comprising levobupivacaine((S)-1-butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide ), that are particularly useful in a patient who is disposed to adverse systemic side-effects, are disclosed.

Analgesic agent and its use

A pharmaceutical dosage form comprises, in one portion thereof, a substantially single (+)-enantiomer of a chiral drug other than verapamil and, in another, separate portion thereof, a substantially single (-)-enantiomer of the drug wherein, in use, the different enantiomers are released at different rates from the dosage form. The dosage form is useful for administration of chiral drugs where both enantiomers have a valid pharmacological input, and where a clinical benefit may be realised by controlling the release rates of those enantiomers. Examples of such drugs include, in particular, tramadol and warfarin.

Pharmaceutical drug dosage forms providing different release rates

Levobupivacaine ((S)-1-butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide) is useful as an anesthetic, particularly in a patient who is CNS-compromised or predisposed to CNS side-effects. It is also useful as an anesthetic in obstetrics.

Growing community of inventors

Cambridge, United Kingdom

Andrew John Richards